![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (82)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (22)
Sempastian Filippas-Ntekouan, Vasilios Tsimihodimos, Theodosios Filippatos, Theodora Dimitriou & Moses Elisaf. (2018) SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. Expert Opinion on Drug Metabolism & Toxicology 14:11, pages 1113-1121.
Read now
Read now
T. D. Filippatos, M. Florentin, M. Georgoula & M. S. Elisaf. (2017) Pharmacological management of diabetic dyslipidemia. Expert Review of Clinical Pharmacology 10:2, pages 187-200.
Read now
Read now
Anastasiya M Kaneva, Natalya N Potolitsyna & Evgeny R Bojko. (2017) Usefulness of the LDL-C/apoB ratio in the overall evaluation of atherogenicity of lipid profile. Archives of Physiology and Biochemistry 123:1, pages 16-22.
Read now
Read now
Matilda Florentin, Michael S Kostapanos, Anastazia Kei & Moses S Elisaf. (2014) Emerging drugs for hyperlipidaemia: an update. Expert Opinion on Emerging Drugs 19:4, pages 471-488.
Read now
Read now
TD Filippatos, CS Derdemezis, PV Voulgari, V Tsimihodimos, MS Elisaf, AD Tselepis & AA Drosos. (2013) Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study. Scandinavian Journal of Rheumatology 42:3, pages 169-175.
Read now
Read now
Theodosios D Filippatos & Moses S Elisaf. (2011) Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opinion on Pharmacotherapy 12:12, pages 1945-1958.
Read now
Read now
Matilda Florentin, Evangelos N Liberopoulos, Dimitri P Mikhailidis & Moses S Elisaf. (2011) Emerging options in the treatment of dyslipidemias: a bright future?. Expert Opinion on Emerging Drugs 16:2, pages 247-270.
Read now
Read now
Aris P Agouridis, Theodosios D Filippatos, Vasilios Tsimihodimos & Moses S Elisaf. (2011) Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism. Expert Review of Cardiovascular Therapy 9:3, pages 355-366.
Read now
Read now
Niki Katsiki, Vasilis G. Athyros, Asterios Karagiannis & Dimitri P. Mikhailidis. (2011) Ezetimibe and low density lipoprotein subfractions: an ongoing debate. Current Medical Research and Opinion 27:3, pages 693-695.
Read now
Read now
Matilda Florentin, Evangelos N. Liberopoulos, Elisavet Moutzouri, Christos V. Rizos, Alexandros D. Tselepis & Moses S. Elisaf. (2011) The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Current Medical Research and Opinion 27:3, pages 685-692.
Read now
Read now
William Insull$suffix/text()$suffix/text(), Peter P Toth, H Robert Superko, Roopal B Thakkar, Scott Krause, Ping Jiang, Rhea A Parreno & Robert J Padley. (2010) Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. Vascular Health and Risk Management 6, pages 1065-1075.
Read now
Read now
Irene F Gazi & Moses S Elisaf. (2010) Effect of infection on lipid profile: focus on Epstein–Barr virus. Clinical Lipidology 5:5, pages 607-610.
Read now
Read now
Maria Sarigianni, Niki Katsiki & Dimitri P Mikhailidis. (2010) Ezetimibe in diabetes: more than cholesterol lowering?. Current Medical Research and Opinion 26:10, pages 2517-2520.
Read now
Read now
CV Rizos, Moses Elisaf, DP Mikhailidis & EN Liberopoulos. (2009) How safe is the use of thiazolidinediones in clinical practice?. Expert Opinion on Drug Safety 8:1, pages 15-32.
Read now
Read now
M Florentin, EN Liberopoulos, TD Filippatos, C Kostara, A Tselepis, DP Mikhailidis & M Elisaf. (2008) Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. Expert Opinion on Pharmacotherapy 9:16, pages 2741-2750.
Read now
Read now
Konstantinos Tziomalos, Vasilios G Athyros, Asterios Karagiannis & Dimitri P Mikhailidis. (2008) Established and emerging vascular risk factors and the development of aortic stenosis: an opportunity for prevention?. Expert Opinion on Therapeutic Targets 12:7, pages 809-820.
Read now
Read now
M Florentin, EN Liberopoulos, DP Mikhailidis & Elisaf MS. (2008) Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 9:10, pages 1705-1720.
Read now
Read now
Vasilios G Athyros, Anna I Kakafika, Konstantinos Tziomalos, Asterios Karagiannis & Dimitri P Mikhailidis. (2008) Antisense technology for the prevention or the treatment of cardiovascular disease: The next blockbuster?. Expert Opinion on Investigational Drugs 17:7, pages 969-972.
Read now
Read now
E. S. Nakou, T. D. Filippatos, M. Georgoula, D. N. Kiortsis, A. D. Tselepis, D. P. Mikhailidis & M. S. Elisaf. (2008) The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Current Medical Research and Opinion 24:7, pages 1919-1929.
Read now
Read now
Vasilios G Athyros, Anna Kakafika, Konstantinos Tziomalos, Asterios Karagiannis & Dimitri P Mikhailidis. (2008) Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?. Expert Opinion on Investigational Drugs 17:4, pages 445-449.
Read now
Read now
Mihalis Kalogirou, Vasilis Tsimihodimos, Irene Gazi, Theodosios Filippatos, Vasilis Saougos, Alexandros D. Tselepis, Dimitri P. Mikhailidis & Moses Elisaf. (2007) Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Current Medical Research and Opinion 23:5, pages 1169-1176.
Read now
Read now
Manfredi Rizzo & Kaspar Berneis. (2007) The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates. Current Medical Research and Opinion 23:5, pages 1103-1111.
Read now
Read now
Articles from other publishers (60)
Vicente Martínez-Vizcaíno, Francisco J. Amaro-Gahete, Rubén Fernández-Rodríguez, Miriam Garrido-Miguel, Iván Cavero-Redondo & Diana P. Pozuelo-Carrascosa. (2021) Effectiveness of Fixed-Dose Combination Therapy (Polypill) Versus Exercise to Improve the Blood-Lipid Profile: A Network Meta-analysis. Sports Medicine 52:5, pages 1161-1173.
Crossref
Crossref
Genovefa Kolovou, Vana Kolovou & Niki Katsiki. (2022) Volanesorsen: A New Era in the Treatment of Severe Hypertriglyceridemia. Journal of Clinical Medicine 11:4, pages 982.
Crossref
Crossref
Emily Bowman & Nicholas T. Funderburg. (2019) Lipidome Abnormalities and Cardiovascular Disease Risk in HIV Infection. Current HIV/AIDS Reports 16:3, pages 214-223.
Crossref
Crossref
Niki Katsiki & Dimitri P Mikhailidis. (2018) Lipids: a personal view of the past decade. Hormones 17:4, pages 461-478.
Crossref
Crossref
Shigemasa Tani, Tsukasa Yagi, Wataru Atsumi, Kenji Kawauchi, Rei Matsuo & Atsushi Hirayama. (2017) Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study. Cardiovascular Diabetology 16:1.
Crossref
Crossref
M. Wölter, C. Röwer, C. Koy, W. Rath, U. Pecks & M.O. Glocker. (2016) Proteoform profiling of peripheral blood serum proteins from pregnant women provides a molecular IUGR signature. Journal of Proteomics 149, pages 44-52.
Crossref
Crossref
Toon van der Gronde, Anita Hartog, Charlotte van Hees, Hubert Pellikaan & Toine Pieters. (2016) Systematic review of the mechanisms and evidence behind the hypocholesterolaemic effects of HPMC, pectin and chitosan in animal trials. Food Chemistry 199, pages 746-759.
Crossref
Crossref
Rae-Ellen W. Kavey. (2015) Combined dyslipidemia in childhood. Journal of Clinical Lipidology 9:5, pages S41-S56.
Crossref
Crossref
Werner Kramer. 2016. Metabolic Control. Metabolic Control
373
435
.
Hisato Takagi, Masao Niwa, Yusuke Mizuno, Hirotaka Yamamoto, Shin-nosuke Goto & Takuya Umemoto. (2013) Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: a meta-analysis of randomized trials. Heart and Vessels 29:3, pages 287-299.
Crossref
Crossref
Sunghwan Suh, Hyung-Doo Park, Sang-Man Jin, Hye Jeong Kim, Ji Cheol Bae, So Young Park, Mi Kyoung Park, Duk Kyu Kim, Nam H Cho & Moon-Kyu Lee. (2013) Diabetes mellitus, but not small dense low-density lipoprotein, is predictive of cardiovascular disease: A Korean community-based prospective cohort study. Journal of Diabetes Investigation 4:6, pages 546-551.
Crossref
Crossref
Theodosios D. Filippatos, Evangelos C. Rizos, Vasilios Tsimihodimos, Irene F. Gazi, Alexandros D. Tselepis & Moses S. Elisaf. (2013) Small High-Density Lipoprotein (HDL) Subclasses are Increased with Decreased Activity of HDL-Associated Phospholipase A2 in Subjects with Prediabetes. Lipids 48:6, pages 547-555.
Crossref
Crossref
T.D. Filippatos, V. Tsimihodimos, C.S. Derdemezis, I.F. Gazi, V. Saougos, D.P. Mikhailidis, A.D. Tselepis & M.S. Elisaf. (2013) Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile. Nutrition, Metabolism and Cardiovascular Diseases 23:4, pages 330-336.
Crossref
Crossref
Ioanna Paspala, Niki Katsiki, Dorothea Kapoukranidou, Dimitri P Mikhailidis & Anna Tsiligiroglou-Fachantidou. (2012) The Role of Psychobiological and Neuroendocrine Mechanisms in Appetite Regulation and Obesity. The Open Cardiovascular Medicine Journal 6:1, pages 147-155.
Crossref
Crossref
Maria Saumoy, Jos? Luis S?nchez-Quesada, Esteban Mart?nez, Josep Maria Llibre, Esteban Ribera, Hernando Knobel, Josep Maria Gatell, Bonaventura Clotet, Adrian Curran, Jordi Curto, Margarita Mas?Jordi Ordo?ez-Llanos & Daniel Podzamczer. (2012) LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy. Atherosclerosis 225:1, pages 200-207.
Crossref
Crossref
Debasis Bagchi & Harry PreussKazuo Miyashita & Masashi Hosokawa. 2012. Obesity. Obesity
651
666
.
Anastazia A. Kei, Theodosios D. Filippatos, Vasilios Tsimihodimos & Moses S. Elisaf. (2012) A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism 61:7, pages 906-921.
Crossref
Crossref
Theodosios D. Filippatos. (2012) A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination. Cardiovascular Drugs and Therapy 26:3, pages 245-255.
Crossref
Crossref
Manfredi Rizzo & Dimitri P. Mikhailidis. (2012)
Lipoprotein alterations and reduced growth hormone secretion: relationships with obesity and cardiovascular risk
1
. Clinical Endocrinology 76:2, pages 177-178.
Crossref
Crossref
Erina ShigematsuTadashi YamakawaMasataka TaguriSatoshi MoritaMikiya TokuiKazunori MiyamotoOsamu FunaeYoji TakatukaKazuaki KadonosonoHiroshi ShigematsuYasuo Terauchi. (2012) Efficacy of Ezetimibe is Associated with Gender and Baseline Lipid Levels in Patients with Type 2 Diabetes. Journal of Atherosclerosis and Thrombosis 19:9, pages 846-853.
Crossref
Crossref
Dorte Rytter, Erik B. Schmidt, Bodil H. Bech, Jeppe H. Christensen, Tine B. Henriksen & Sjurdur F. Olsen. (2011) Fish Oil Supplementation During Late Pregnancy Does Not Influence Plasma Lipids or Lipoprotein Levels in Young Adult Offspring. Lipids 46:12, pages 1091-1099.
Crossref
Crossref
Kazuo Miyashita, Bhaskar Narayan, Takayuki Tsukui, Hiroyuki Kamogawa, Masayuki Abe & Masashi Hosokawa. 2011. Handbook of Marine Macroalgae. Handbook of Marine Macroalgae
329
339
.
Irene F. Gazi, Fotini A. Apostolou, Evangelos N. Liberopoulos, Theodosios D. Filippatos, Constantinos C. Tellis, Moses S. Elisaf & Alexandros D. Tselepis. (2011) Leptospirosis is Associated with Markedly Increased Triglycerides and Small Dense Low-Density Lipoprotein and Decreased High-Density Lipoprotein. Lipids 46:10, pages 953-960.
Crossref
Crossref
Eliot A. Brinton, Moti L. Kashyap, Anthony N. Vo, Roopal B. Thakkar, Ping Jiang & Robert J. Padley. (2011) Niacin Extended-Release Therapy in Phase III Clinical Trials is Associated with Relatively Low Rates of Drug Discontinuation due to Flushing and Treatment-Related Adverse Events. American Journal Cardiovascular Drugs 11:3, pages 179-187.
Crossref
Crossref
Maria Saumoy, Jordi Ordoñez-Llanos, Esteban Martínez, Patricia Barragán, Esteban Ribera, Rosa Bonet, Hernando Knobel, Eugenia Negredo, Montserrat Loncá, Adrian Curran, Josep Maria Gatell & Daniel Podzamczer. (2010) Low-Density Lipoprotein Size and Lipoprotein-Associated Phospholipase A2 in HIV-Infected Patients Switching to Abacavir or Tenofovir. Antiviral Therapy 16:4, pages 459-468.
Crossref
Crossref
Jisuk Yun, Ji Young Kim, Oh Yoen Kim, Yangsoo Jang, Jey Sook Chae, Jung Hyun Kwak, Hyo Hee Lim, Hyun Young Park, Sang-Hyun Lee & Jong Ho Lee. (2011) Associations of plasma homocysteine level with brachial-ankle pulse wave velocity, LDL atherogenicity, and inflammation profile in healthy men. Nutrition, Metabolism and Cardiovascular Diseases 21:2, pages 136-143.
Crossref
Crossref
F. Apostolou, I.F. Gazi, K. Lagos, C.C. Tellis, A.D. Tselepis, E.N. Liberopoulos & M. Elisaf. (2010) Acute infection with Epstein?Barr virus is associated with atherogenic lipid changes. Atherosclerosis 212:2, pages 607-613.
Crossref
Crossref
Manfredi RizzoJelena Vekic, Spyridon Koulouris, Aleksandra Zeljkovic, Zorana Jelic-Ivanovic, Vesna Spasojevic-Kalimanovska, Giovam Battista Rini, Dimitrios Sakellariou, Socrates Pastromas, Dimitri P. Mikhailidis & Antonis S. Manolis. (2010) Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes. Angiology 61:6, pages 584-590.
Crossref
Crossref
K. Berneis, M. Rizzo, H. K. Berthold, G. A. Spinas, W. Krone & I. Gouni-Berthold. (2010) Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. European Heart Journal 31:13, pages 1633-1639.
Crossref
Crossref
Christos S. Derdemezis, Theodosios D. Filippatos, Dimitri P. Mikhailidis & Moses S. Elisaf. (2010) Review Article: Effects of Plant Sterols and Stanols Beyond Low-Density Lipoprotein Cholesterol Lowering. Journal of Cardiovascular Pharmacology and Therapeutics 15:2, pages 120-134.
Crossref
Crossref
Yasunori Sawayama, Shinji Maeda, Hachiro Ohnishi, Shin Hayashi & Jun Hayashi. (2010) Efficacy and Safety of Ezetimibe for Japanese Patients with Dyslipidaemia. Clinical Drug Investigation 30:3, pages 157-166.
Crossref
Crossref
Theodosios D Filippatos. (2010) Combination drug treatment in patients with non-alcoholic fatty liver disease. World Journal of Hepatology 2:4, pages 139.
Crossref
Crossref
Theodosios D Filippatos. (2010) Combination drug treatment in obese diabetic patients. World Journal of Diabetes 1:1, pages 8.
Crossref
Crossref
Juan Gabriel Calle Luna, Miguel Boronat García, María Dolores Albaladejo Otón, Esteban Granero Fernández, Antonio Miguel Hernández Martínez & Soledad Parra Pallarés. (2010) Evaluación de un método electroforético para el subfraccionamiento de las partículas plasmáticas de lipoproteínas de baja densidad. Revista del Laboratorio Clínico 3:1, pages 31-36.
Crossref
Crossref
F. Apostolou, I.F. Gazi, A. Kostoula, C.C. Tellis, A.D. Tselepis, M. Elisaf & E.N. Liberopoulos. (2009) Persistence of an atherogenic lipid profile after treatment of acute infection with brucella. Journal of Lipid Research 50:12, pages 2532-2539.
Crossref
Crossref
Matilda Florentin, Michael S. Kostapanos, Eleni S. Nakou, Moses ElisafEvangelos N. Liberopoulos. (2009) Efficacy and Safety of Ezetimibe Plus Orlistat or Rimonabant in Statin-Intolerant Nondiabetic Overweight/Obese Patients With Dyslipidemia. Journal of Cardiovascular Pharmacology and Therapeutics 14:4, pages 274-282.
Crossref
Crossref
Manfredi Rizzo, Giatgen A Spinas, Mustafa Cesur, Zeynep Ozbalkan, Giovam Battista Rini & Kaspar Berneis. (2009) Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis. Atherosclerosis 207:2, pages 502-506.
Crossref
Crossref
Jadwiga Hartwich, Malgorzata Malczewska Malec, Lukasz Partyka, Pablo Pérez-Martinez, Carmen Marin, Jose López-Miranda, Audrey C. Tierney, Jolene Mc Monagle, Helen M. Roche, Catherine Defoort, Pawel Wolkow & Aldona Dembinska-Kieć. (2009) The effect of the plasma n-3/n-6 polyunsaturated fatty acid ratio on the dietary LDL phenotype transformation – Insights from the LIPGENE study. Clinical Nutrition 28:5, pages 510-515.
Crossref
Crossref
M. Hanefeld. (2009) The role of pioglitazone in modifying the atherogenic lipoprotein profile. Diabetes, Obesity and Metabolism 11:8, pages 742-756.
Crossref
Crossref
Kaspar Berneis, Manfredi Rizzo, Giatgen A. Spinas, Gabriele Di Lorenzo, Gaetana Di Fede, Ilenia Pepe, Vincenzo Pernice & Giovam Battista Rini. (2009) The predictive role of atherogenic dyslipidemia in subjects with non-coronary atherosclerosis. Clinica Chimica Acta 406:1-2, pages 36-40.
Crossref
Crossref
TD Filippatos, CS Derdemezis & MS Elisaf. (2009) Effects of orlistat, alone or combined with hypolipidemic drugs, on cardiovascular risk factors. Clinical Lipidology 4:3, pages 331-341.
Crossref
Crossref
Manfredi Rizzo, Giovam Battista Rini, Giatgen A. Spinas & Kaspar Berneis. (2009) The effects of ezetimibe on LDL-cholesterol: Quantitative or qualitative changes?. Atherosclerosis 204:2, pages 330-333.
Crossref
Crossref
Manfredi Rizzo, Jelena Kotur-Stevuljevic, Kaspar Berneis, Giatgen Spinas, Giovam Battista Rini, Zorana Jelic-Ivanovic, Vesna Spasojevic-Kalimanovska & Jelena Vekic. (2009) Atherogenic dyslipidemia and oxidative stress: a new look. Translational Research 153:5, pages 217-223.
Crossref
Crossref
Constantinos C. Tellis & Alexandros D. Tselepis. (2009) Τhe role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1791:5, pages 327-338.
Crossref
Crossref
Jan H van Ee. (2009) Soy constituents: modes of action in low-density lipoprotein management. Nutrition Reviews 67:4, pages 222-234.
Crossref
Crossref
T.D. Filippatos, E.N. Liberopoulos, N. Pavlidis, M.S. Elisaf & D.P. Mikhailidis. (2009) Effects of hormonal treatment on lipids in patients with cancer. Cancer Treatment Reviews 35:2, pages 175-184.
Crossref
Crossref
K. G. Lagos, T. D. Filippatos, V. Tsimihodimos, I. F. Gazi, C. Rizos, A. D. Tselepis, D. P. Mikhailidis & Moses S. Elisaf. (2008) Alterations in the High Density Lipoprotein Phenotype and HDL-Associated Enzymes in Subjects with Metabolic Syndrome. Lipids 44:1, pages 9-16.
Crossref
Crossref
Sammy Y Chan, GB John Mancini, Andrew Ignaszewski & Jiri Frohlich. (2008) Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study. BMC Clinical Pharmacology 8:1.
Crossref
Crossref
Konstantinos Tziomalos, Vasilios G. Athyros, Asterios Karagiannis & Dimitri P. Mikhailidis. (2008) Omega-3 fatty acids: How can they be used in secondary prevention?. Current Atherosclerosis Reports 10:6, pages 510-517.
Crossref
Crossref
Wolfgang Leonhardt, Andreas Pf?tzner, J?rgen M?ller, Jens Pietzsch, Thomas Forst, Efstrathios Karagiannis, Georg L?bben & Markolf Hanefeld. (2008) Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study. Atherosclerosis 201:1, pages 155-162.
Crossref
Crossref
H. Robert Superko & Radhika R. Gadesam. (2008) Is it LDL particle size or number that correlates with risk for cardiovascular disease?. Current Atherosclerosis Reports 10:5, pages 377-385.
Crossref
Crossref
Konstantinos Tziomalos, Charitha N. Weerasinghe, Dimitri P. Mikhailidis & Alexander M. Seifalian. (2008) Vascular risk factors in South Asians. International Journal of Cardiology 128:1, pages 5-16.
Crossref
Crossref
. (2008) Current World Literature. Current Opinion in Endocrinology, Diabetes & Obesity 15:2, pages 193-219.
Crossref
Crossref
M. John Chapman & Andrei C. Sposito. (2008) Hypertension and dyslipidaemia in obesity and insulin resistance: Pathophysiology, impact on atherosclerotic disease and pharmacotherapy. Pharmacology & Therapeutics 117:3, pages 354-373.
Crossref
Crossref
Irene F. Gazi, Haralampos J. Milionis, Theodosios D. Filippatos, Vasilis Tsimihodimos, Michael S. Kostapanos, Michael Doumas, Alexandros D. Tselepis & Moses Elisaf. (2008) Hypertriglyceridaemic waist phenotype criteria and prevalent metabolic triad in women. Diabetes/Metabolism Research and Reviews 24:3, pages 223-230.
Crossref
Crossref
U. Julius, M. Dittrich & J. Pietzsch. (2007) Factors influencing the formation of small dense low-density lipoprotein particles in dependence on the presence of the metabolic syndrome and on the degree of glucose intolerance. International Journal of Clinical Practice 61:11, pages 1798-1804.
Crossref
Crossref
Vasilios G. Athyros, Anna I. Kakafika, Athanasios A. Papageorgiou, Konstantinos Tziomalos, Athanasios Skaperdas, Efstathios Pagourelias, Athina Pirpasopoulou, Asterios Karagiannis & Dimitri P. Mikhailidis. (2007) Atorvastatin Decreases Triacylglycerol-Associated Risk of Vascular Events in Coronary Heart Disease Patients. Lipids 42:11, pages 999-1009.
Crossref
Crossref
Manfredi RizzoKaspar Berneis. (2007) Update on the role of the atherogenic lipoprotein phenotype in cardiovascular prevention. Future Cardiology 3:5, pages 553-558.
Crossref
Crossref
R. Donnelly. (2007) Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes. International Journal of Clinical Practice 61:7, pages 1160-1169.
Crossref
Crossref
Manfredi Rizzo, Giovam Battista Rini & Kaspar Berneis. (2007) Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: The modulation of LDL size and subclasses in high-risk patients. Advances in Therapy 24:3, pages 575-582.
Crossref
Crossref